Avastin (bevacizumab) / Roche |
ACTRN12622001514796: KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme |
|
|
| Recruiting | N/A | 18 | | | Royal Adelaide Hospital, Neurosurgical Research Foundation | Glioblastoma Multiforme | | | | |
ACTRN12622000675729: Leveraging Chimeric Antigen Receptor-Expressing T Cells for Children with Diffuse Midline Glioma |
|
|
| Recruiting | N/A | 18 | | | Sydney Children's Hospitals Network, Levi's Project, Australian Philanthropic Services, Cancer Institute NSW, Medical Research Future Fund, Australian Government Department of Health, Cure Cancer Australia Foundation | Central Nervous System Tumour, Diffuse Midline Glioma, High Grade Glioma, Diffuse Intrinsic Pontine Glioma | | | | |
| Recruiting | N/A | 200 | | | The University of Sydney, National Health Medical Research Council | Cancer, Cardio Vascular Disease | | | | |
ChiCTR-TRC-09000697: Effects of Different Dosages of intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Randomized Controlled Trial |
|
|
| Completed | N/A | 50 | | 1.25mg intravitreal bevacizumab at monthly interval 3 to 6 months versus 2.5mg intravitreal bevacizumab | NA; Level of the institution:, Department of Ophthalmology and Visual Sciences | Neovascular age-related macular degeneration | | | | |
ChiCTR-TRC-09000698: Effect of Different Dosages of Intravitreal Bevacizumab (Avastin) in the Treatment of Diabetic Macular Edema: A Randomized Controlled Trial |
|
|
| Completed | N/A | 52 | | 1.25mg intravitreal bevacizumab at monthly 3 months versus 2.5mg intravitreal bevacizumab | NA; Level of the institution:, Department of Ophthalmology and Visual Sciences | Diabetic Macular Edema | | | | |
ChiCTR-TRC-09000696: The Safety and Efficacy of Combined Subtenon Triamcinolone Acetonide, Intravitreal Bevacizumab and Grid Laser Photocoagulation for Refractory Diabetic Macular Edema - A Pilot Study |
|
|
| Completed | N/A | 30 | | Subtenon triamcinolone, intravitreal bevacizumab injections and macular photocoagulation 2 months | NA; None, Department of Ophthalmology and Visual Sciences The Chinese University of Hong Kong | Refractory diabetic macular edema | | | | |
NCT00372866: Chemotherapy and Bevacizumab in Treating Women With Invasive Breast Cancer |
|
|
| Recruiting | N/A | 30 | US | bevacizumab, filgrastim, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, adjuvant therapy | Premiere Oncology | Breast Cancer | | | | |
NCT01301547: Bevacizumab and Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin in Treating Patients With Refractory Solid Tumors |
|
|
| Recruiting | N/A | 20 | US | bevacizumab, polyethyleneglycol-7-ethyl-10-hydroxycamptothecin, protein expression analysis, laboratory biomarker analysis | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 09/11 | | | |
ChiCTR-TRC-08000711: Needling with adjunctive intravitreal injection of bevacizumab (avastin). A preliminary study. |
|
|
| Completed | N/A | 30 | | Needling with intravitreal injection of Bevacizumab (Avastin) vs No control or comparative treatment for this study for 10 to 15min | NA; Level of the institution:, Departmental funding from DOVS, CUHK (for the drug bevacizumab (avastin)) | Glaucoma | | | | |
ChiCTR-ONC-08000714: Intravitreal injection of Bevacizumab (Avastin) as an adjunctive therapy of pterygium surgery to prevent recurrence: A pilot study |
|
|
| Completed | N/A | 50 | | Intravitreal injection of Bevacizumab (Avastin?) after surgical excision of pterygium immediately | NA; Level of the institution:, NA | pterygium | | | | |
ChiCTR-TRC-10000973: Study of exogenous endothelial progenitor cell in enhancing the antitumor effect of bevacizumab for recurrent ovarian cancer |
|
|
| Completed | N/A | 20 | | exogenous endothelial progenitor cell plus Bevacizumab ;Bevacizumab alone | Third military medical university; Third military medical university, The clinical research fund of third military medical university | recurrent ovarian cancer | | | | |
| Completed | N/A | 180 | | Traditional chemotherapy ;Traditional chemotherapy+Bevacizumab ;Traditional chemotherapy+CIK ;chemotherapy+Bevacizumab+CIK ;Traditional chemotherapy+Megestrol ;Traditional chemotherapy+Bevacizumab+CIK+Megestrol | First Affiliated Hospital, Shenzhen University, Futian District, Shenzhen, Guangdong Province; Level of the institution:, Shenzhen Innovation Committee | Inoperable hepatocellular carcinoma | | | | |
ChiCTR1800018768: Evaluation Of The Efficacy And Safety Of Intrapleural Injection Of Bevacizumab Treatment Of Malignant Pleural Effusion Caused By Lung Adenocarcinoma |
|
|
| Recruiting | N/A | 60 | | thoracic perfusion therapy ;thoracic perfusion therapy | The Affiliated Hospital of Inner Mongolia Medical University; The Affiliated Hospital of Inner Mongolia Medical University, The Affiliated Hospital of Inner Mongolia Medical University | Malignant Pleural Effusion Caused By Lung Adenocarcinoma | | | | |
ChiCTR-IOD-16009803: The effect of ultra low dose of bevacizumab for brain radiation necrosis of the brain |
|
|
| Recruiting | N/A | 30 | | 5mg/kg Bevacizumab ;1 mg/kg Bevacizumab | Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital, Wu Jieping fund | Brain radiation necrosis | | | | |
NCT06559488: IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes |
|
|
| Completed | N/A | 18 | RoW | Bevacizumab Injection [Avastin], Pars Plana Vitrectomy | Universitas Padjadjaran, Cicendo Eye Hospital | Diabetic Retinopathy, Vitreous Hemorrhage | 03/19 | 03/19 | | |
| Not yet recruiting | N/A | 30 | | ultra-low dose Bevacizumab plus Temozolomide | Hebei Yanda Hospital; Hebei Yanda Hospital, Supported by Hebei Yanda Hospital | Recurrent High-grade Glioma | | | | |
| Completed | N/A | 279 | RoW | Transarterial chemoembolization, TACE, Systemic treatment | Zhejiang University | Hepatocellular Carcinoma | 03/23 | 10/23 | | |
ChiCTR1800016652: Real-world data analysis of bevacizumab in patients with non-squamous non-small cell lung cancer Study Protocol |
|
|
| Not yet recruiting | N/A | 1000 | | NA | Shanghai Chest Hospital, Shanghai Jiaotong University; Shanghai Chest Hospital, Shanghai Jiaotong University, Beijing Bethune Public Welfare Foundation | Non-small cell lung cancer | | | | |
ChiCTR1900023502: Clinical effects and early assessment of high intensity focused ultrasound combined with bevacizumab in the treatment of colorectal liver metastases |
|
|
| Not yet recruiting | N/A | 90 | | HIFU ;bevacizumab ;HIFU+bevacizumab | Huadong Hospital; Huadong Hospital, Huadong Hospital Project | colorectal cancer | | | | |
ChiCTR-IOR-16009658: A precision medicine-based clinical study of screening targeted drug combined with chemotherapy for the treatment of primary advanced ovarian cancer |
|
|
| Not yet recruiting | N/A | 400 | | Carboplatin+Paclitaxel ;Bevacizumab+Carboplatin+Paclitaxel ;Dosage according to the combination use of 3D bioprinting technology and dose recommended by the pharmacodynamics ;Dosage according to the recommended dose of international clinical trial phase III(GOG-0218) | Department of Gynecology and Obstetrics, Renji Hospital Affiliated to Shanghai JiaoTong University School of Medicine; Ren Ji Hospital Affiliated to Shanghai JiaoTong University School of Medicine, School of Medicine, Shanghai Jiao Tong University | Ovarian Cancer | | | | |
NCT01993043: 39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity |
|
|
| Completed | N/A | 150 | US | | Baylor College of Medicine | ROP Threshold | 10/20 | 09/23 | | |
ACTRN12624000463572: Randomised Clinical Trial: Influence of Subconjunctival Anaesthesia Duration on Pain Perception During Intravitreal Injections |
|
|
| Completed | N/A | 240 | | | Jiyeon Kim, Christchurch Public Hospital, Eye clinic | intravitreal injection pain, age-related macular degeneration, retinal vein occlusion, diabetic macular oedema | | | | |
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 240 | RoW | Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab | 12/24 | 12/24 | | |
ABCHCaen, NCT06416683: Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma |
|
|
| Completed | N/A | 109 | Europe | | University Hospital, Caen | Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | 06/23 | 01/24 | | |
NCT04446793: Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer |
|
|
| No Longer Available | N/A | | NA | Onvansertib, Bevacizumab, FOLFIRI | Cardiff Oncology | Metastatic Colorectal Cancer, KRAS Gene Mutation | | | | |
ChiCTR2100042595: Short Term and Sustained EyePressure Changes after Intraocular injection of Bevacizumab in Diabetic Retinopathy Patients |
|
|
| Completed | N/A | 42 | | intravitreal bevacisumab | University of Health Sciences, Lahore, Pakistan; Gujranwala Medical College, Nil | Diabetic Retinopathy | | | | |
NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial |
|
|
| No Longer Available | N/A | | US | TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda | Tracon Pharmaceuticals Inc. | Solid Tumors | | | | |
NCT04601688: Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. |
|
|
| Not yet recruiting | N/A | 100 | RoW | Bevacizumab Ophthalmic and Intravitreal Dexamethasone, Avastin®, Ozurdex®, Bevacizumab Ophthalmic | He Eye Hospital | Branch Retinal Vein Occlusion | 03/21 | 09/21 | | |
NCT06199297: Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma |
|
|
| Completed | N/A | 188 | RoW | Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy | Sun Yat-sen University | Hepatocellular Carcinoma | 07/23 | 07/23 | | |
NCT04601701: Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. |
|
|
| Recruiting | N/A | 100 | RoW | Bevacizumab Ophthalmic and Intravitreal Dexamethasone., Avastin®, Ozurdex®, Bevacizumab Ophthalmic. | He Eye Hospital | Central Retinal Vein Occlusion | 03/21 | 09/21 | | |
NCT03286738: Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 1800 | RoW | FOLFIRI, target agent | Joong Bae Ahn | Metastatic Colorectal Cancer | 12/21 | 12/21 | | |
NCT05080803: Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome |
|
|
| Completed | N/A | 608 | Europe | intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone | European School of Advanced Studies in Ophthalmology | Diabetic Macular Edema | 12/21 | 07/22 | | |
ChiCTR2000034017: Study on the clinical benefits of reoperation in patients with recurrent glioblastoma |
|
|
| Not yet recruiting | N/A | 180 | | Maximum range of brain tumor resection +/ chemotherapy (temozolomide/bevacizumab)+/ radiotherapy + adjuvant therapy ;Maximum range of brain tumor resection +adjuvant therapy ;Chemotherapy (temozolomide/bevacizumab)+/ radiotherapy + adjuvant therapy ;Chemotherapy (temozolomide/bevacizumab)+ adjuvant therapy | Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University, Investigator sponsored | Glioblastoma | | | | |
| Completed | N/A | 23 | Europe | bevacizumab treatment | Hospices Civils de Lyon | Hemorrhagic Hereditary Telangiectasia, HHT | 01/22 | 08/22 | | |
ChiCTR2000041205: Treating Leukoencephalopathy With Calcifications and Cysts With Bevacizumab |
|
|
| Completed | N/A | 1 | | bevacizumab | The First Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital, School of Medicine, Zhejiang University, Medical insurance and self-payment | Inherited Leukoencepalopathy | | | | |
ASTRAL-HCC, UMIN000045131: An Exploratory Serum Cytokine Analysis of Atezolizumab + Bevacizumab Combination Therapy in Patients With Hepatocellular Carcinoma: A Multicenter Prospective Observational Study |
|
|
| Enrolling by invitation | N/A | 20 | Japan | Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche | National Center for Global Health and Medicine Hospital, National Center for Global Health and Medicine | Hepatocellular Carcinoma | | | | |
NCT04684095: The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 338 | RoW | electronic patient report outcome | Harbin Medical University | Colorectal Cancer Metastatic, Cancer | 02/22 | 06/24 | | |
ChiCTR2100052354: Real world study on safety and economic evaluation of bevacizumab quality system |
|
|
| Not yet recruiting | N/A | 200 | | No | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Supported by Shanghai Aisha Medical Technology Co., Ltd | rectal cancer | | | | |
ROBOT, NCT04213222: Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | N/A | 300 | RoW | Bevacizumab | Peking University People's Hospital | Colon Cancer, Rectal Cancer, Liver Metastases | 06/22 | 12/23 | | |
ChiCTR2200061793: Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study |
|
|
| Completed | N/A | 30 | | None | The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University; The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University, Self-raised | hepatocellular carcinoma complicated with portal vein tumor thrombus | | | | |
| Recruiting | N/A | 400 | Europe | Microdebrider, Cold-steel surgery (forceps), Carbon dioxide laser, Potassium titanyl phosphate (KTP) laser, Pulsed dye laser, Radiofrequency ablation, Monopolar suction diathermy, Plasma coagulation, Other, Adjuvant therapies, Acyclovir, Artemisinin, Bevacizumab (Avastin), Celecoxib (Celebrex), Cidofovir, Cimetidine, Di-indolmethane (DIM), Gardasil, Indole-3-carbinol (I3C), alpha-Interferon, PEG-Interferon, Methotrexate, Retinoic acid (isotretinoin), Ribavarin | Newcastle-upon-Tyne Hospitals NHS Trust, Alder Hey Children's NHS Foundation Trust, National Institute for Health Research, United Kingdom | Recurrent Respiratory Papillomatosis, Human Papilloma Virus | 08/22 | 08/22 | | |
COBRA, NCT03451370: First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | N/A | 121 | Europe | Capecitabine, Oxaliplatin, Bevacizumab | Istituto Oncologico Veneto IRCCS | Elderly Metastatic Colorectal Cancer Patients | 07/24 | 12/24 | | |
EVA DOPA, NCT04566185: Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma |
|
|
| Recruiting | N/A | 30 | Europe | FDG PET, CT scan, Magnetic resonance imaging (MRI) | Centre Hospitalier Universitaire de Nīmes | Glioblastoma | 09/22 | 09/22 | | |
NCT05544812: A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer |
|
|
| Recruiting | N/A | 10 | RoW | Sintilimab ,bevcizumab/cetuximab,XELOX | Xijing Hospital | Colorectal Cancer | 09/22 | 06/23 | | |
NCT04446416: Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients |
|
|
| Completed | N/A | 6 | RoW | NaviFUS System, Bevacizumab, Avastin | NaviFUS Corporation, Chang Gung Memorial Hospital | Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue | 09/22 | 08/23 | | |
ChiCTR2000036117: Study on the diagnosis and treatment strategy of neurofibromatosis type 2 based on evidence-based medicine |
|
|
| Not yet recruiting | N/A | 80 | | Cochlear implant ;Treatment of Avastin ;follow-up observation | Ninth Perople's Hospital, Shanghai Jiao Tong University School of Medicine; Hospital Development Center, Hospital Development Center | Neurofibromatosis type 2 | | | | |
NCT06031376: Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC |
|
|
| Completed | N/A | 106 | RoW | Fruquintinib, PD-1 inhibitors, anti-PD-1 antibodies, Trifluridine/Tipiracil, TAS-102, Lonsurf, S 95005, Bevacizumab, Avastin | Hunan Cancer Hospital | Metastatic Colorectal Adenocarcinoma | 10/22 | 03/23 | | |
NCT05869097: Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 90 | RoW | Trifluridine/Tipiracil, TAS-102, Lonsurf, S 95005, Bevacizumab, Avastin | Hunan Cancer Hospital | Metastatic Colorectal Adenocarcinoma | 10/22 | 04/23 | | |
RANT, NCT05277675: Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma ( Study) |
|
|
| Recruiting | N/A | 160 | RoW | Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab, RFA | Southwest Hospital, China | Hepatocellular Carcinoma Recurrent | 11/22 | 10/23 | | |
ChiCTR2000040267: A prospective, single-arm, single-center clinical study of anlotinib hydrochloride for maintenance treatment of patients with advanced non-small cell lung cancer after chemotherapy combined with bevacizumab as first-line treatment |
|
|
| Not yet recruiting | N/A | 30 | | Oral Anlotinib 12mg/qd, Stop using for one week after two consecutive weeks,Q3W, until disease progression | Xingtai People's Hospital; Xingtai People's Hospital, self-financing | Non-small cell lung cancer | | | | |
ChiCTR1900027023: A non-inferiority study of apatinib versus bevacizumab combined with XELOX regimen in the treatment of metastatic colorectal cancer |
|
|
| Recruiting | N/A | 120 | | Apatinib 250mg po, qd, continuous taken; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w ;Bevacizumab 7.5mg/kg, q3w; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w | Tangshan People's Hospital; Tangshan people's Hospital, self-raise | colorectal cancer | | | | |
ChiCTR2000031722: A non-interventional, single-arm, prospective clinical study for the efficacy and safety of gefitinib combined with bevacizumab and pemetrexed in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer. |
|
|
| Recruiting | N/A | 200 | | gefitinib, bevacizumab and pemetrexed | Shandong Cancer Hospital; Shandong Cancer Hospital, Self-finance | Lung Cancer | | | | |
ChiCTR2000036551: Establishment and validation of therapeutic effect prediction model of first line treatment of bevacizumab combined with mFOLFOX6 in Ras mutant colorectal cancer patients with liver metastasis |
|
|
| Not yet recruiting | N/A | | | | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shanghai Shenkang Hospital Development Center | colorectal cancer | | | | |
NCT04862949: Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC |
|
|
| Completed | N/A | 124 | RoW | Atezolizumab plus bevacizumab | CHA University, Hoffmann-La Roche | Advanced Hepatocellular Carcinoma | 12/22 | 03/23 | | |
NCT06023173: Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases |
|
|
| Completed | N/A | 307 | RoW | Deep radiomics-based fusion model, deep learning model | Fudan University | The Patients With CRLM Who Benefit More From Bevacizumab | 01/23 | 01/23 | | |
| Completed | N/A | 5 | Europe | Sentinel lymph node identification, SLN | Meander Medical Center, Meander Medisch Centrum | Colonic Neoplasms, Sentinel Lymph Node, Fluorescence, Colorectal Neoplasms | 02/23 | 06/23 | | |
ChiCTR2200064495: Association Analysis of VEGF Inhibitors with Vascular Calcification: A Retrospective Study of Patients with Colorectal or Renal Cancer Treated with Bevacizumab |
|
|
| Not yet recruiting | N/A | | | none | Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Self-funded | Vascular Calcification Occurs in Patients with Colorectal or Kidney Cancer | | | | |
ChiCTR2100051286: The efficacy and safety of Yadanzi oil injection in the treatment of advanced colon cancer |
|
|
| Recruiting | N/A | 60 | | Basic chemotherapy + Bevacizumab + Yadanzi oil injection ;Basic chemotherapy + Bevacizumab | Shanxi Provincial Hospital of Traditional Chinese Medicine; Shanxi Provincial Hospital of Traditional Chinese Medicine, Department of Oncology, Shanxi Provincial Hospital of Traditional Chinese Medicine | advanced colon cancer | | | | |
BELLA, NCT04575415: Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study |
|
|
| Recruiting | N/A | 272 | RoW | Bevacizumab, Avastin, Erlotinib, Tarceva, Gefitinib, Iressa, Icotinib, Conmana, Afatinib, Gilotrif, Dacomitinib, Vizimpro, Osimertinib, Tagrisso | Guangdong Association of Clinical Trials | NSCLC | 05/23 | 12/23 | | |
NCT05410938: Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy |
|
|
| Completed | N/A | 59 | RoW | Chemotherapy | Far Eastern Memorial Hospital | Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer | 05/23 | 05/23 | | |
BETTER, NCT05407155: Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 56 | NA | bevacizumab plus nab-paclitaxel and platinum | Fudan University | Non-small Cell Lung Cancer Metastatic | 06/23 | 06/24 | | |
NCT06119347: Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors |
|
|
| Completed | N/A | 1581 | RoW | AntiVEGF, ICIs | First Affiliated Hospital of Wenzhou Medical University | AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs | 06/23 | 10/23 | | |
ChiCTR2200055514: Effect of half-dose BYVASDA versus standard dose Avastin combined with mFOLFOX6 chemotherapy on metastatic colorectal cancer : A multicenter, open-label, parallel, randomized controlled clinical study |
|
|
| Recruiting | N/A | 571 | | mFOLFOX6 +half-dose Bevacizumab (BYVASDA) ;mFOLFOX6 + half-dose Bevacizumab (Avastin) | Sichuan Cancer Hospital; Sichuan Cancer Hospital, self-financing and corporate sponsorship | metastatic colorectal cancer | | | | |
NCT05703750: Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) |
|
|
| Recruiting | N/A | 228 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
NCT05704192: CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) |
|
|
| Recruiting | N/A | 373 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
| Recruiting | N/A | 478 | Europe | XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy | Radboud University Medical Center, Erasmus Medical Center | Multi-organ Metastatic Colorectal Cancer | 07/23 | 07/25 | | |
NCT03648814: Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT |
|
|
| Recruiting | N/A | 70 | RoW | Intracameral injection, Intravitreal injection | Prince of Songkla University | Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression | 07/23 | 07/23 | | |
ChiCTR2200061510: Clinical data analysis of bevacizumab-induced hypertension in patients with colorectal cancer |
|
|
| Completed | N/A | 1054 | | None | The Sixth Affiliated Hospital of Sun Yat-Sen University; The Sixth Affiliated Hospital of Sun Yat-Sen University, Self-funded | Colorectal cancer | | | | |
ChiCTR2000034451: Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project |
|
|
| Not yet recruiting | N/A | 50 | | afatinib combined with bevacizumab | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Association of Oncology | NSCLC | | | | |
| Completed | N/A | 5 | Europe | Sentinel lymph node detection using intravenous bevacizumab-800CW | Meander Medical Center, Meander Medisch Centrum | Colorectal Neoplasms, Colon Neoplasm, Sentinel Lymph Node, Fluorescence | 07/23 | 10/23 | | |
NCT05781633: The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer. |
|
|
| Recruiting | N/A | 43 | RoW | eutidrone etoposide bevacizumab | Tianjin Medical University Cancer Institute and Hospital | Mammary Neoplasms, Human | 07/23 | 07/25 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT03647592: Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 30 | RoW | Erlotinib/Gefitinib combined with Bevacizumab, treatment of A+T | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 08/24 | 12/25 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
ChiCTR2100050957: A multi-cohort real-world study of the efficacy and safety of bevacizumab in advanced recurrent ovarian cancer |
|
|
| Recruiting | N/A | 200 | | 6 cycles of bevacizumab IBI305 combined with platinum-containing doublet chemotherapy followed by 16 cycles of bevacizumab IBI305 maintenance therapy ;Bevacizumab in combination with non-platinum chemotherapy | The Second People's Hospital of Anhui Province; The Second People's Hospital of Anhui Province, self-funded | Advanced recurrent ovarian cancer | | | | |
ChiCTR2100050106: An exploratory clinical study of fluzoparib combined with bevacizumab in the maintenance treatment of RAS mutant colorectal cancer after first-line chemotherapy |
|
|
| Not yet recruiting | N/A | 30 | | fluzoparib combined with bevacizumab | Shanghai Dongfang Hospital; Shanghai Dongfang Hospital, Expenditure of department | RAS mutant colorectal cancer | | | | |
SCENIC, NCT06292286: Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer |
|
|
| Recruiting | N/A | 18 | RoW | Carboplatin or cisplatin, Paraplatin or Platinol, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Taxol, Gemzar, Caelyx, Bevacizumab or biosimilar, Avastin or mvasi, Cytoreductive surgery | The University of Hong Kong | Recurrent Ovarian Carcinoma | 12/25 | 07/26 | | |
ChiCTR2100043740: Clinical observation of Ascending Lucidity Descending Turbidity Decoction combined with bevacizumab intracavitary injection in the treatment of malignant serous cavities effusion |
|
|
| Recruiting | N/A | 60 | | ascending lucidity descending turbidity decoction orally ;bevacizumab intracavitary injection | Shenzhen Hospital of Beijing University of Traditional Chinese Medicine (Longgang); Shenzhen Hospital of Beijing University of traditional Chinese medicine (Longgang), Project funds of 'Yulong talent' training plan in 2020 | Malignant serous cavity effusion | | | | |
NCT04770376: Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab |
|
|
| Recruiting | N/A | 150 | Europe | Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy. | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale SS Giovanni e Paolo, Venezia | Ovarian Cancer | 12/23 | 12/23 | | |
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study |
|
|
| Not yet recruiting | N/A | 200 | NA | TACE, Atezolizumab, Bevacizumab | Zhongda Hospital | HCC | 12/23 | 06/24 | | |
| Completed | N/A | 208 | RoW | Lenvatinib | Sun Yat-sen University | Hepatocellular Carcinoma, Lenvatinib | 03/24 | 05/24 | | |
ChiCTR2000037472: An open labeled, randomized controlled phase II pilot trial of systematic treatment with or without SBRT in the management of gynecologic cancer with first line chemotherapy induced oligo metastasis |
|
|
| Not yet recruiting | N/A | 120 | | paclitaxel plus cisplatin or carboplatin with or without Bevacizumab ;paclitaxel plus cisplatin or carboplatin + PD-1 checkpoint inhibitor with or without Bevacizumab ;paclitaxel plus cisplatin or carboplatin with or without Bevacizumab, combined oligo-metastasis SBRT ;paclitaxel plus cisplatin or carboplatin+PD-1 checkpoint inhibitor with or without Bevacizumab, combined oligo-metastasis SBRT | Shanghai First Maternity and Infant Hospital; Shanghai First Maternity and Infant Hospital, Shanghai Hospital Development Center | Gyenecological cancer | | | | |
ChiCTR2000037649: Hypofractionated Stereotactic Radiotherapy With PD-L1 Inhibitor and Bevacizumab in Patients With Recurrent High-Grade Gliomas: a Prospective Single Center Exploratory Clinical Trial |
|
|
| Not yet recruiting | N/A | 32 | China | Hypofractionated Stereotactic Radiotherapy + Durvalumab+ Bevacizumab | Huashan Hospital, Fudan University ; Huashan Hospital, Fudan University, Huashan Hospital, Fudan University | High-Grade Glioma | | | | |
ChiCTR2100043395: Gefitinib plus pemetrexed combined with bevacizumab or carboplatin in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer. |
|
|
| Recruiting | N/A | 309 | | Gefitinib plus pemetrexed and bevacizumab ;Gefitinib plus pemetrexed and carboplatin | Shandong Cancer Hospital; 440 Jiyan Street, Huaiyin District, Self-finance | Lung Cancer | | | | |
ChiCTR2100045399: TCM evidence-based capacity building and evidence-based implementation plan of TCM combined with chemotherapy in treatment of metastatic colorectal cancer:A bidirectional cohort study of Zhenqiliujun anti-cancer granules combined with mFOLFOX6/FOLFIRI regimen and bevacizumab/cetuximab in first-line treatment of advanced metastatic colorectal |
|
|
| Recruiting | N/A | 362 | | MFOLFOX6 /FOLFIRI regimen + bevacizumab/cetuximab + Zhenqi Liujun cancer suppressant granules. ;MFOLFOX6 /FOLFIRI + bevacizumab/cetuximab | Department of Oncology, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University; The Traditional Chinese Medicine Hospital Affiliated to Southwest, National Administration ofnTraditional Chinese Medicine | colorectal cancer | | | | |
ChiCTR2100046780: Post marketing safety and economic evaluation of bevacizumab injection |
|
|
| Recruiting | N/A | 3100 | | None ;None ;None ;None | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wu Jieping Medical Foundation | Non small cell lung cancer | | | | |
NCT05173298: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab |
|
|
| Recruiting | N/A | 100 | RoW | atezolizumab plus bevacizumab | CHA University, Boryung Pharmaceutical Co., Ltd | Advanced Hepatocellular Carcinoma | 07/24 | 12/24 | | |
| Recruiting | N/A | 300 | RoW | TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga | Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma Non-resectable | 12/23 | 12/24 | | |
STAR-T, NCT05839951: An Observational Study Called to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions |
|
|
| Active, not recruiting | N/A | 818 | US | Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab | Bayer | Metastatic Colorectal Cancer (mCRC) | 10/24 | 10/24 | | |
ZG005-IIT-001, NCT06233994: A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 30 | RoW | ZG005 Powder for Injection, ZG005, Donafenib Tosilate Tablets, Donafenib, Bevacizumab | Changsha Taihe Hospital | Advanced Hepatocellular Carcinoma | 01/26 | 01/26 | | |
DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | N/A | 39 | RoW | DEBIRI Combined With Chemotherapy and Bevacizumab | Fudan University | Colorectal Neoplasms | 01/25 | 05/25 | | |
NCT06265350: Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases |
|
|
| Recruiting | N/A | 80 | RoW | Cadonilimab, Bevacizumab, Cryoablation | Sun Yat-sen University | Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab, Bevacizumab, Cryoablation | 01/26 | 01/27 | | |
NCT06244446: Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. |
|
|
| Not yet recruiting | N/A | 40 | RoW | No intervention | Institute of Liver and Biliary Sciences, India | Advanced Hepatocellular Carcinoma | 01/25 | 01/25 | | |
ChiCTR2200055254: Exploratory study on the efficacy of utidelone combined with capecitabine and bevacizumab in the treatment of brain metastasis of HER2 negative breast cancer |
|
|
| Recruiting | N/A | 29 | | utidelone combined with capecitabine and bevacizumab | Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, Beijing Heath Medical Oncology Research Foundation | breast cancer | | | | |
ChiCTR2200057280: Efficacy and safety of low-dose afatinib combined with bevacizumab and pemetrexate in first-line treatment of stage IV lung adenocarcinoma with EGFR mutation |
|
|
| Recruiting | N/A | 100 | | low-dose alfaatinib combined with bevacizumab and pemetrexed | Shandong Cancer Hospital; Shandong Cancer Hospital, self-funded | Lung Cancer | | | | |
ATTRACT, NCT04944069: Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis |
|
|
| Not yet recruiting | N/A | 69 | RoW | Almonertinib, Bevacizumab | Second Affiliated Hospital of Nanchang University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation | 03/24 | 03/25 | | |
| Recruiting | N/A | 70 | Europe | Fluorescence guided detection of tumor positive margins. | University Medical Center Groningen, Martini Hospital Groningen | Breast Cancer, Breast Cancer Invasive | 09/24 | 12/24 | | |
NCT06349044: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. |
|
|
| Recruiting | N/A | 120 | RoW | Hypofractionated radiotherapy/SBRT(5-10Gy/fx,3-5 fx), Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine, Anti-VEGF 15mg/kg, Anti-VEGF 7.5mg/kg, Gemcitabine and Cisplatin | Zhejiang Cancer Hospital | Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma | 12/25 | 12/25 | | |
NCT05211804: Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse |
|
|
| Completed | N/A | 31 | Europe | Ophthalmic Drugs, Aflibercept, Bevacizumab, Ranibizumab | Sorlandet Hospital HF | Wet Macular Degeneration | 05/24 | 05/24 | | |
NCT03698162: Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases |
|
|
| Terminated | N/A | 14 | US | Dynamic Contrast-Enhanced Magnetic Resonance Imaging, DCE MRI, DCE-MRI, DYNAMIC CONTRAST ENHANCED MRI, Bevacizumab Injection, Avastin | University of Southern California, National Cancer Institute (NCI) | Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma | 11/23 | 11/23 | | |